Citigroup’s Cogent Biosciences COGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $13.9M | Buy |
433,693
+253,234
| +140% | +$9.36M | ﹤0.01% | 1409 |
|
|
2026
Q2 | $6.98M | Buy |
180,459
+147,534
| +448% | +$5.16M | ﹤0.01% | 1868 |
|
|
2026
Q1 | $1.27M | Sell |
32,925
-35,728
| -52% | -$1.32M | ﹤0.01% | 2966 |
|
|
2025
Q4 | $2.44M | Buy |
68,653
+54,245
| +376% | +$1.52M | ﹤0.01% | 2526 |
|
|
2025
Q3 | $207K | Sell |
14,408
-45,317
| -76% | -$537K | ﹤0.01% | 3980 |
|
|
2025
Q2 | $429K | Sell |
59,725
-137,282
| -70% | -$761K | ﹤0.01% | 3716 |
|
|
2025
Q1 | $1.18M | Buy |
197,007
+52,553
| +36% | +$412K | ﹤0.01% | 3132 |
|
|
2024
Q4 | $1.13M | Buy |
144,454
+76,038
| +111% | +$758K | ﹤0.01% | 3273 |
|
|
2024
Q3 | $739K | Buy |
68,416
+29,086
| +74% | +$283K | ﹤0.01% | 3485 |
|
|
2024
Q2 | $332K | Sell |
39,330
-560,659
| -93% | -$4.25M | ﹤0.01% | 3634 |
|
|
2024
Q1 | $4.03M | Buy |
599,989
+478,138
| +392% | +$2.96M | ﹤0.01% | 1876 |
|
|
2023
Q4 | $716K | Buy |
121,851
+39,610
| +48% | +$304K | ﹤0.01% | 3113 |
|
|
2023
Q3 | $802K | Buy |
82,241
+2,522
| +3% | +$29.9K | ﹤0.01% | 2683 |
|
|
2023
Q2 | $944K | Sell |
79,719
-114,871
| -59% | -$1.32M | ﹤0.01% | 2886 |
|
|
2023
Q1 | $2.1M | Buy |
194,590
+50,605
| +35% | +$647K | ﹤0.01% | 1992 |
|
|
2022
Q4 | $1.66M | Sell |
143,985
-48,287
| -25% | -$598K | ﹤0.01% | 2190 |
|
|
2022
Q3 | $2.87M | Buy |
192,272
+57,268
| +42% | +$785K | ﹤0.01% | 1895 |
|
|
2022
Q2 | $1.22M | Buy |
135,004
+1,235
| +0.9% | +$8.43K | ﹤0.01% | 2484 |
|
|
2022
Q1 | $1M | Sell |
133,769
-8,229
| -6% | -$57.3K | ﹤0.01% | 2947 |
|
|
2021
Q4 | $1.22M | Sell |
141,998
-112,681
| -44% | -$980K | ﹤0.01% | 3052 |
|
|
2021
Q3 | $2.14M | Buy |
254,679
+216
| +0.1% | +$1.66K | ﹤0.01% | 2490 |
|
|
2021
Q2 | $2.06M | Sell |
254,463
-38,851
| -13% | -$328K | ﹤0.01% | 2641 |
|
|
2021
Q1 | $2.58M | Buy |
293,314
+253,048
| +628% | +$2.44M | ﹤0.01% | 2323 |
|
|
2020
Q4 | $452K | Buy |
+40,266
| New | +$442K | ﹤0.01% | 4295 |
|
|
2020
Q1 | – | Sell |
-538
| Closed | -$2K | – | 7619 |
|
|
2019
Q4 | $2K | Buy |
538
+1
| +0.2% | +$4 | ﹤0.01% | 7539 |
|
|
2019
Q3 | $3K | Hold |
537
| – | – | ﹤0.01% | 7445 |
|
|
2019
Q2 | $6K | Sell |
537
-888
| -62% | -$11.8K | ﹤0.01% | 7429 |
|
|
2019
Q1 | $25K | Buy |
1,425
+326
| +30% | +$5.57K | ﹤0.01% | 6830 |
|
|
2018
Q4 | $19K | Buy |
1,099
+855
| +350% | +$25.3K | ﹤0.01% | 6895 |
|
|
2018
Q3 | $10K | Buy |
244
+117
| +92% | +$6.6K | ﹤0.01% | 7343 |
|
|
2018
Q2 | $7K | Buy |
+127
| New | +$6.1K | ﹤0.01% | 7271 |
|
Other funds holding COGT
Citigroup's COGT Position: Q3 2026 in Review
Citigroup increased its Cogent Biosciences (COGT) stake by 140% in Q3 2026, buying an estimated $9.36M and bringing the position to 433,693 shares worth $13.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1409.
Citigroup first reported a position in COGT in Q2 2018 and has held it in 31 quarters since. 76 funds tracked by Wall St. Rank hold COGT as of Q3 2026.
- Citigroup held 433,693 shares of Cogent Biosciences worth $13.9M as of Q3 2026.
- Citigroup bought 253,234 Cogent Biosciences shares in Q3 2026, an estimated $9.36M.
- Cogent Biosciences made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #1409 holding.
- Citigroup first reported a position in Cogent Biosciences in Q2 2018 and has held it in 31 quarters since.
- 76 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2026.
Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.